Imatinib mesylate potentiates topotecan antitumor activity in rhabdomyosarcoma preclinical models.

MLA

McDowell, Heather P., et al. “Imatinib Mesylate Potentiates Topotecan Antitumor Activity in Rhabdomyosarcoma Preclinical Models.” International Journal of Cancer, vol. 120, no. 5, Mar. 2007, pp. 1141–49. EBSCOhost, https://doi.org/10.1002/ijc.22391.

APA

McDowell, H. P., Meco, D., Riccardi, A., Tanno, B., Berardi, A. C., Raschellà, G., Riccardi, R., & Dominici, C. (2007). Imatinib mesylate potentiates topotecan antitumor activity in rhabdomyosarcoma preclinical models. International Journal of Cancer, 120(5), 1141–1149. https://doi.org/10.1002/ijc.22391

Chicago

McDowell, Heather P, Daniela Meco, Anna Riccardi, Barbara Tanno, Anna C Berardi, Giuseppe Raschellà, Riccardo Riccardi, and Carlo Dominici. 2007. “Imatinib Mesylate Potentiates Topotecan Antitumor Activity in Rhabdomyosarcoma Preclinical Models.” International Journal of Cancer 120 (5): 1141–49. doi:10.1002/ijc.22391.